Valuation models
price $229.94 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused180.35 – 258.96212.208% overvaluedDCF · Perpetuity growth · 10y199.71 – 285.46234.492% undervaluedDCF · EBITDA exit · 5y262.80 – 285.17273.6916% undervaluedDCF · EBITDA exit · 10y266.29 – 308.67286.4820% undervaluedP/E · peers177.32 – 254.77212.198% overvaluedP/E · own history303.11 – 464.54380.8140% undervaluedPEG—142.4061% overvaluedEV/EBITDA · peers161.89 – 315.09230.23at modelEV/Revenue · peers80.33 – 166.38122.3688% overvaluedEarnings power value86.22 – 122.43101.04128% overvaluedDividend discount40.98 – 107.7261.56274% overvaluedWall St. consensus target—262.0012% belowCost of capital (WACC)—8.28%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
212.20
ResMed closed at $229.94 — overvalued by 8% vs model.
180.35the model's range258.96
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
61.56 – 380.81
Wall St. target
262.00 12% below
Above model, 1y
15 of 30 days
How it is valued
Valued asMature & Stable
Low/slowing growth (~10% recent)High profitability (27% net margin)Pays dividendsHighly cyclical earningsStrong FCF yield (5.1%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.